Results 261 to 270 of about 121,067 (308)
“Couldst thou not watch with me?”: Queer Orientation and Unresponse in Swinburne’s ‘A Wasted Vigil’
VJ René
openalex +2 more sources
Corrigendum: Assessment of risk scores to predict mortality of COVID-19 patients admitted to the intensive care unit. [PDF]
Nogueira MCA+41 more
europepmc +1 more source
Effect of a SARS-CoV-2 Protein Fragment on the Amyloidogenic Propensity of Human Islet Amyloid Polypeptide. [PDF]
Bilog M+4 more
europepmc +1 more source
A growing body of literature suggests that courts and juries are inclined toward division of liability between two strictly non-negligent or 'vigilant' parties. However, standard models of liability rules do not provide for vigilance-based sharing of liability.
Allan M. Feldman, Ram Singh
openaire +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
, 2021
5502 Background: In the VITAL (NCT02346747) trial, maintenance therapy with Vigil, an autologous tumor cell vaccine transfected with a DNA plasmid encoding GMCSF and bi-shRNA-furin for TGFβ expression control, following frontline platinum-based ...
R. Rocconi+12 more
semanticscholar +1 more source
5502 Background: In the VITAL (NCT02346747) trial, maintenance therapy with Vigil, an autologous tumor cell vaccine transfected with a DNA plasmid encoding GMCSF and bi-shRNA-furin for TGFβ expression control, following frontline platinum-based ...
R. Rocconi+12 more
semanticscholar +1 more source
The structure of vigilance [PDF]
Vigilance is understood as a primarily behavioral category. Identical stimuli tend to evoke more or less differentiated behavioral responses dependent on a low or high state of vigilance. The rise of vigilance from coma to full attention moves along with increasing differentiation of evoked behavioral responses. With heterogeneous physical, figurative,
openaire +2 more sources
, 2020
3002Background: Recent studies have shown poor clinical outcomes and limited survival advantage to checkpoint inhibitors (CIs) in advanced stage ovarian cancer (OvC).
R. Rocconi+14 more
semanticscholar +1 more source
3002Background: Recent studies have shown poor clinical outcomes and limited survival advantage to checkpoint inhibitors (CIs) in advanced stage ovarian cancer (OvC).
R. Rocconi+14 more
semanticscholar +1 more source